Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:11 PM
Ignite Modification Date:
2025-12-24 @ 12:11 PM
NCT ID:
NCT00916461
Eligibility Criteria:
Inclusion Criteria:
* Aged 18 to 65 years
* Diagnostic and Statistical Manual-IV (DSM-IV) diagnosed first episode psychosis, schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder
* First episode (within first 5 years of diagnosis)
* Competent and willing to give informed consent
* Medication remained stable 4 weeks prior to baseline
* Able to take oral medication and likely to complete the required evaluations
* Female participants of child bearing capability must be willing to use adequate contraceptives for the duration of the study, and, willing to have a pregnancy test pre-treatment and at ten weekly intervals while on study medication
Exclusion Criteria:
* Relevant medical illness \[renal, hepatic, cardiac, serious dermatological disorders such as exfoliative dermatitis, systemic lupus erythematosus (SLE)\] in the opinion of the investigators (see section 6.2a)
* Prior history of intolerance to any of the tetracyclines
* Concomitant penicillin therapy
* Concomitant anticoagulant therapy
* Presence of a seizure disorder, not including clozapine-induced seizures
* Presently taking valproic acid
* Any change of psychotropic medications within the previous six weeks
* Diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last three months according to DSM-IV criteria
* Pregnant or breast-feeding
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT00916461
Study Brief:
Protocol Section:
NCT00916461